Bio-Path Holdings Shifts Focus to Metabolic Program

Bio-Path Holdings ( (BPTH) ) just unveiled an announcement.

Bio-Path Holdings announced its strategic focus on the development of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients, supported by scientific evidence linking Grb2 protein downregulation to improved insulin signaling and lower blood glucose levels. The company has decided to reallocate resources to its metabolic program while discontinuing the Phase 1 study of BP1002 for certain blood cancers due to enrollment challenges, indicating a shift in priorities that may impact its operational strategy and market focus.

More about Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company that develops targeted nucleic acid cancer drugs using its proprietary DNAbilize® liposomal delivery and antisense technology. The company focuses on creating RNAi nanoparticle drugs, including its lead product candidate, prexigebersen (BP1001), which targets the Grb2 protein for blood cancers, and BP1001-A, a modified version for solid tumors.

YTD Price Performance: -92.28%

Average Trading Volume: 1,201,981

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $3.08M

For detailed information about BPTH stock, go to TipRanks’ Stock Analysis page.